 OraSure Technologies Inc NASDAQ: OSUR has submitted an application to the FDA seeking Emergency Use Authorization EUA for its COVID-19 rapid antigen test for both Prescription Home Use and Professional Use in point of care POC settings. These lateral flow, rapid diagnostic tests are designed to detect active COVID-19 infection, using samples self-collected from the lower nostrils. 